Welcome to our dedicated page for Regencell Bioscience Holdings news (Ticker: RGC), a resource for investors and traders seeking the latest updates and insights on Regencell Bioscience Holdings stock.
Regencell Bioscience Holdings Limited (NASDAQ: RGC) generates news primarily around its Traditional Chinese Medicine (TCM) research and development programs for ADHD, ASD and COVID-19. Company announcements describe it as an early-stage bioscience company focused on TCM-based liquid formulae for neurocognitive disorders and infectious diseases that affect the immune system.
News coverage for RGC often centers on efficacy trial updates. For ADHD and ASD, Regencell has reported results from a first research study using personalized TCM formulae in Hong Kong and interim results from a second efficacy trial using standardized TCM formulae in children clinically diagnosed with ADHD and/or ASD. These updates discuss assessment tools such as the Sik-Kee Au TCM Brain Theory® Assessment (SKATBT-A3), the Vanderbilt ADHD Diagnostic Parent Rating Scale (VADRS) and the Autism Treatment Evaluation Checklist (ATEC), as well as reported changes in symptoms and overall physical and neurodevelopmental conditions.
Another major stream of news relates to COVID-19 programs. Regencell has announced results from its EARTH and EARTH-B non-blinded efficacy trials of the investigational liquid formula RGC-COV19TM, reporting on symptom elimination timelines, RT-PCR testing outcomes in Malaysia, and the absence of reported unknown adverse side effects or treatment-emergent adverse events. These releases emphasize that the results have not yet been peer-reviewed and that RGC-COV19TM remains investigational.
Investors following RGC can also find corporate and capital markets news, including inclusion in the MSCI World Micro Cap Index, insider share purchases disclosed via Schedule 13D filings, joint venture formation to offer COVID-19 related treatments in ASEAN countries, India, Japan, Australia and New Zealand, and board and committee changes reported on Form 6‑K. This news page allows readers to track these developments in one place and review how Regencell’s TCM-focused strategy is reflected in its public communications over time.
Regencell Bioscience Holdings Limited (NASDAQ:RGC) announced that its underwriter exercised an option to purchase 325,000 additional ordinary shares at $9.50 each as part of its initial public offering (IPO). The total gross proceeds of the IPO, including this option, reached $24,937,500, before expenses. Funds will be allocated to research studies, product development, staff salaries, and corporate expenses. The company specializes in Traditional Chinese Medicine for neurocognitive disorders like ADHD and ASD, aiming to commercialize liquid-based TCM formulae for these conditions.
Regencell Bioscience Holdings Limited (NASDAQ: RGC) has announced significant milestones and future plans in a letter from CEO Yat-Gai Au. The company focuses on Traditional Chinese Medicine (TCM) for treating neurocognitive disorders like ADHD and ASD. Regencell raised approximately $19.3 million from its IPO on July 16, 2021, aimed at funding further research and development. Following a successful initial study showing reduced symptoms in ADHD and ASD patients, a second study is set to begin next month, with 100 participants. The outcome will support future proprietary medicine registration.
Regencell Bioscience Holdings Limited (NASDAQ:RGC) announced the closing of its initial public offering, raising $21.9 million by offering 2,300,000 ordinary shares at $9.50 per share. The company has also granted underwriters a 45-day option for an additional 345,000 shares. Proceeds will fund a second research study, product development, salaries, and other operational costs. Registered with the SEC, the offering enables Regencell to advance its focus on Traditional Chinese Medicine for ADHD and ASD treatments.
Regencell Bioscience Holdings Limited (NASDAQ:RGC) announced its initial public offering of 2,300,000 ordinary shares priced at $9.50 each, expecting gross proceeds of about $21.9 million. The shares will trade on the Nasdaq Capital Market starting July 16, 2021. Proceeds will fund research initiatives, TCM development, staff costs, and general corporate purposes. The offering is set to close around July 20, 2021, pending customary conditions. Maxim Group LLC is the sole book-running manager for the offering.